

Ce-M-M-

Research Center for Molecular Medicine
of the Austrian Academy of Sciences

Apply
now!

Met -
Val-His-Leu-Thr-
Pro-Glu-Glu-Lys-Ser-Ala-
Val-Thr-Ala-Leu-Trp-Gly-Lys-
Val-Asn-Val-Asp-Glu-Val-Gly-Gly-
Glu-Ala-Leu-Gly-Arg-Leu-Leu-Val-Val-
Tyr-Pro-Trp-Thr-Gin-Arg-Phe-Phe-Glu-Ser-
Phe-Gly-Asp-Leu-Ser-Thr-Pro-Asp-Ala-Val-
Met-Gly-Asn-Pro-Lys-Val-Lys-Ala-His-Gly-
Lys-Lys-Val-Leu-Gly-Ala-Phe-Ser-Asp-
Gly-Leu-Ala-His-Leu-Asp-Asn-Leu-Lys-
Gly-Thr-Phe-Ala-Thr-Leu-Ser-Glu-Leu-
His-Cys-Asp-Lys-Leu-His-Val-Asp-Pro-
Glu-Asn-Phe-Arg-Leu-Leu-Gly-Asn-Val-
Leu-Val-Cys-Val-Leu-Ala-His-His-Phe-
Gly-Lys-Glu-Phe-Thr-Pro-Pro-Val-
Gin-Ala-Ala-Tyr-Gin-Lys-Val-Val-
Ala-Gly-Val-Ala-Asn-Ala-Leu-Ala-
His-Lys-Tyr-His-Met-Val-Leu-Ser-Pro-
Ala-Asp-Lys-Thr-Asn-Val-Lys-Ala-
Ala-Trp-Gly-Lys-Val-Gly-Ala-His-Ala-
Gly-Glu-Tyr-Gly-Ala-Glu-Ala-Leu-Glu-Arg-
Met-Phe-Leu-Ser-Phe-Pro-Thr-Thr-Thr-Tyr-
Phe-Pro-His-Phe-Asp-Leu-Ser-His-Gly-Ser-Ala-Gin-
Val-Lys-Gly-His-Gly-Lys-Lys-Val-Ala-Asp-Ala-Leu-Thr-
Asn-Ala-Val-Ala-His-Val-Asp-Asp-Met-Pro-Asn-Ala-
Leu-Ser-Ala-Leu-Ser-Asp-Leu-His-Ala-His-Lys-Leu-Arg-
Val-Asp-Pro-Val-Asn-Phe-Lys-Leu-Ser-His-Cys-Leu-
Val-Thr-Leu-Ala-Ala-His-Leu-Pro-Ala-Glu-Phe-Thr-Pro-
Ala-Ser-Leu-Asp-Lys-Phe-Leu-Ala-Ser-Val-Ser-Thr-Val-
Tyr-Arg-Met-Val-His-Leu-Thr-Pro-Glu-Glu-Lys-Ser-
Gly-Lys-Val-Asn-Val-Asp-Glu-Val-Gly-Gly-Ala-Leu-Gly-Arg-Leu-Leu-Val-Val-Tyr-
Pro-Trp-Thr-Gin-Arg-Phe-Phe-Glu-Ser-Phe-Gly-Asp-Leu-Ser-Thr-Pro-Asp-Ala-Val-Met-
Gly-Asn-Pro-Lys-Val-Lys-Ala-His-Gly-Lys-Lys-Val-Leu-Gly-Ala-Phe-Ser-Gly-Leu-Ala-His-
Leu-Asp-Asn-Leu-Lys-Gly-Thr-Phe-Ala-Thr-Leu-Ser-Glu-Leu-His-Cys-Asp-Lys-Leu-His-Val-Asp-
Pro-Glu-Asn-Phe-Arg-Leu-Leu-Gly-Asn-Val-Leu-Val-Cys-Val-Leu-Ala-His-His-Phe-Gly-Lys-Glu-
Met-
Val-His-Leu-Thr-
Pro-Glu-Glu-Lys-Ser-Ala-Val-
Thr-Ala-Leu-Trp-Gly-Lys-Val-Asn-
Val-Asp-Glu-Val-Gly-Gly-Glu-Ala-
Leu-Gly-Arg-Leu-Leu-Val-Val-Tyr-
Pro-Trp-Thr-Gin-Arg-Phe-Phe-Glu-
Ser-Phe-Gly-Asp-Leu-Ser-Thr-Pro-
Asp-Ala-Val-Met-Gly-Asn-Pro-Lys-
Val-Lys-Ala-His-Gly-Lys-Lys-Val-Leu-
Gly-Ala-Phe-Ser-Asp-Gly-Leu-Ala-His-
Leu-Asp-Asn-Leu-Lys-Gly-Thr-Phe-
Ala-Thr-Leu-Ser-Glu-Leu-His-Cys-
Asp-Lys-Leu-His-Val-Asp-Pro-Glu-
Asn-Phe-Arg-Leu-Leu-Gly-
Val-Leu-Val-Cys-Val-Leu-
Ala-His-
His-Phe-Gly-Lys-Glu-
Phe-Thr-
Pro-Pro-Val-Gin-Ala-Tyr-Gin-
Lys-Val-Val-Ala-Gly-Val-Ala-Asn-
Ala-Leu-Ala-His-Lys-Tyr-His-
Met-Val-Leu-Ser-Pro-Ala-Asp-Lys-
Thr-Asn-Val-Lys-Ala-Ala-Trp-Gly-Lys-Val-
Gly-Ala-His-Ala-Gly-Glu-Tyr-Gly-Ala-Glu-Ala-
Leu-Glu-Arg-Met-Phe-Leu-Ser-Phe-Pro-Thr-Thr-
Lys-Thr-Tyr-Phe-Pro-His-Phe-Asp-Leu-Ser-His-
Gly-Ser-Ala-Gin-Val-Lys-Gly-His-Gly-Lys-Lys-Val-
Ala-Asp-Ala-Leu-Thr-Asn-Ala-Val-Ala-His-Val-Asp-
Asp-Met-Pro-Asn-Ala-Leu-Ser-Ala-Leu-Ser-Asp-Leu-
His-Ala-His-Lys-Leu-Arg-Val-Asp-Pro-Val-Asn-Phe-
Lys-Leu-Leu-Ser-His-Cys-Leu-Leu-Val-Thr-Leu-Ala-
Ala-His-Leu-Pro-His-Glu-Phe-Thr-Pro-His-Val-His-
Ala-Ser-Leu-Asp-Lys-Phe-Leu-Ala-Ser-Val-Ser-Thr-
Val-Leu-Thr-Ser-Lys-Tyr-Arg-Met-Val-His-Lys-

Project Scientist in Assay Development to join the Superti-Furga Lab at CeMM

Apply now

Do you want to be part of an international consortium committed to characterize human transporters at the interface between biological systems and the environment?

We are looking for a **project scientist** to develop **cell-based transport assays** to monitor the activity of cellular transporters of the solute carrier group (SLCs). The successful candidate will be part of the RESOLUTE consortium (<https://re-solute.eu/>) and will be based in Giulio Superti-Furga's laboratory (CeMM, Vienna). She/he will project-lead the generation of novel approaches to study SLCs functionally in close exchange with a group of 120 scientists, distributed over 6 pharmaceutical companies, 1 biotech and 6 academic research institutions, constituting a powerful and unique professional network.

Requirements and desired qualifications

- PhD in cell biology, biochemistry, biotechnology or similar
- Knowledge of general molecular biology and biochemical techniques
- Experience in mammalian cell culture (immortalized cell line models)
- Excellent skills in planning, designing and trouble-shooting cell-based assays
- Basic knowledge in HPLC-mass spectrometry is considered a plus
- Experience with biochemical/pharmacological analysis of transporters or membrane proteins is desirable
- Meticulousness and talent in organization
- Ability to work in a team and pursue goals in a focused way
- Excellent written / oral communication skills in English

The RESOLUTE consortium

Starting on July 1st of 2018, the RESOLUTE consortium is supported by the Innovative Medicines Initiative (IMI, www.imi.europa.eu) with 13 partners from academia and the pharmaceutical industry and is coordinated by the Superti-Furga laboratory. The RESOLUTE consortium's mission is to de-orphanize human SLC transporters at a large scale and unlock them as potential pharmacological targets. With a well-defined action plan, we are currently pushing towards a paradigm-shift in the science of human cellular transporters by creating a massive, historical advance in knowledge on hundreds of individual transporters and the way they act together. These are very exciting times and research and the consortium is reaching full speed and thriving on synergies to turn this large effort into exploitable and practical knowledge.

The Superti-Furga laboratory

The Superti-Furga group (<http://superti-furga-lab.at/>) is composed of an international team of more than 30 scientists working together on understanding drug function at the molecular level. The laboratory investigates how cells and biological systems in general manage access to the environment through cellular transport. In particular how access to nutrients and energy source is tuned to metabolism and need of individual cell types. Moreover, the lab has pioneered approaches for functional precision medicine. The laboratory operates on a truly multidisciplinary basis and involves functional genomics and proteomics, structural analysis, chemical biology, high-content imaging, bioinformatics and physiology, reflecting the blend of expertise of the laboratory members.

Selected publications:

Bigenzahn et al, LZTR1 is a regulator of RAS ubiquitination and signaling, Science 2018.

Rebsamen et al, SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1, Nature 2015.

Cesar- Razquin et al, A Call for Systematic Research on Solute Carriers, Cell 2015.

The Institute

CeMM (www.cemm.at) is a flagship institute for biomedical research in the heart of Europe, Vienna. CeMM is committed to highest scientific standards. The environment is very collaborative, dynamic and international. One of CeMM's advantages is to be in close proximity to the Vienna Medical University Campus and the General Hospital (AKH). This allows the fruitful interaction of basic scientists with clinicians, and the use of models and cutting-edge technology to disease-relevant biological questions. According to a study by The Scientist, CeMM is ranked as the best European place to work in Academia 2012, internationally CeMM appears at the fourth place. The official language at CeMM is English, and more than 45 different nationalities are represented at the institute.

We offer

This is a fantastic opportunity for a project scientist to join an exciting project in an inspiring and dynamic setting. In return we are offering an excellent employee benefits package including health insurance, company health care, competitive holiday allowance, daily bonus for the in-house cafeteria and an **monthly gross salary of EUR 3.889,50,-** (following [the recommendations of the FWF](#)). We offer a great work environment for

passionate scientists and we are proud to be an international, diverse group. The contract for the position will be limited to 3 years since the project terminates in 2023. Other projects are likely to ensue.

Application details

CeMM aims to promote equality of opportunity for all with the right mix of talent, competences and potential. We welcome applications from candidates with diverse backgrounds. Please click on the link <https://cemm.jobbase.io/job/y0jauupk> to apply online with your application documents (cover letter, CV and names and contact details of 2 referees).

Closing date for applications: 9th April 2020. Applications will be reviewed on a rolling basis. The preferred starting date is June/July 2020.

Additional information

City	Vienna
Position type	Full-time employee
Start of work	01.06.2020

Responsible

Alexa Gavalaki

Apply now